Abstract

Background: The spliceosome plays an important role in mRNA alternative splicing and is aberrantly expressed in several tumors. However, the potential roles of spliceosome-related genes in the progression of hepatocellular carcinoma (HCC) remain poorly understood. Materials and Methods: Patient data were acquired from public databases. Expression differences and survival analyses were used to assess the importance of spliceosome-related genes in HCC prognosis. To explore the potential regulatory mechanisms of these genes, a protein-protein interaction network was constructed and screened using univariate and multivariate Cox regression and random forest analyses. This was used to create a five-gene prognostic model. The prognostic value and predictive power of the five-gene signature were assessed using the Kaplan-Meier and time-dependent receiver operating characteristic analyses in the training set. These results were further validated in an independent external set. To facilitate clinical application, a nomogram was prepared to predict the overall survival of HCC patients. The relative expression of five genes was detected using real-time quantitative polymerase chain reaction. Results: The analysis revealed that LSM1-7, SNRPB, SNRPD1-3, SNRPE, SNRPF, SNRPG, and SNRPN could be used as prognostic biomarkers in HCC patients. Moreover, the five-gene risk model could clearly distinguish between the high-and low-risk groups. Furthermore, the risk model was associated with the tumor mutation burden, immune cell infiltration of CD8+ T cells, natural killer T cells, M2 macrophages, and immune checkpoint inhibitors, which also demonstrated the predictive efficacy of this risk model in HCC immunotherapy. Conclusion: Spliceosome-related genes and the five-gene signature could serve as novel prognostic biomarkers for HCC patients, aiding clinical patient monitoring and follow-up.

Highlights

  • Hepatocellular carcinoma (HCC) is a malignant tumor that is associated with high morbidity and low advanced survival rates worldwide (Bray et al, 2018)

  • The analysis revealed that LSM1-7, SNRPB, SNRPD1-3, SNRPE, SNRPF, SNRPG, and SNRPN could be used as prognostic biomarkers in HCC patients

  • The risk model was associated with the tumor mutation burden, immune cell infiltration of CD8+ T cells, natural killer T cells, M2 macrophages, and immune checkpoint inhibitors, which demonstrated the predictive efficacy of this risk model in HCC immunotherapy

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is a malignant tumor that is associated with high morbidity and low advanced survival rates worldwide (Bray et al, 2018). The spliceosome consists of five small nuclear ribonucleoproteins (snRNP; U1, U2, U4, U5, and U6), and the Lsm/sm proteins form the core scaffold of snRNP (Roth et al, 2018). SnRNP genes have been regarded as oncogenic in glioblastoma (Correa et al, 2016), and their high expression is correlated with poor prognosis in non-small cell lung cancer (Valles et al, 2012). Contradictory to these findings, snRNPs were identified as metastasis suppressor genes in prostate cancer (Yi et al, 2009), highlighting their diverse roles. The potential roles of spliceosomerelated genes in the progression of hepatocellular carcinoma (HCC) remain poorly understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call